| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
22,194 | 17,696 | 6,698 | 1,331 | 961 | ||
Research and development - licenses acquired | ||||||
1,000 | 0 | - | - | - | ||
Research and development - licenses acquired | ||||||
- | - | 1,103 | 49 | 3,040 | ||
General and administrative | ||||||
3,071 | 4,120 | 3,620 | 997 | 842 | ||
Loss from operations | ||||||
-26,265 | -21,816 | -11,421 | -2,377 | -4,843 | ||
Interest income | ||||||
357 | 93 | 88 | 0 | 0 | ||
Interest expense | ||||||
- | - | 294 | 420 | 215 | ||
Interest expense - related party | ||||||
- | - | 81 | 192 | 168 | ||
Change in fair value of convertible notes payable | ||||||
- | - | 99 | 0 | 0 | ||
Change in fair value of warrant liabilities | ||||||
- | - | 451 | 188 | 0 | ||
Other income | ||||||
0 | 175 | 0 | - | - | ||
Net Loss | ||||||
-25,908 | -21,548 | -12,258 | -3,177 | -5,226 | ||
Net loss per common share outstanding, basic and diluted | ||||||
-1.65 | -2.10 | -1.85 | -1.11 | -1.93 | ||
Weighted average number of common shares outstanding, basic and diluted | ||||||
15,721 | 10,239 | 6,634 | 2,860 | 2,702 | ||